Orexo AB ADRs commence trading on OTCQX in the U.S.

Uppsala, Sweden – November 13, 2013 – Orexo AB, “Orexo” (OTCQX: ORXOY; NASDAQ
OMX Stockholm: ORX) announces that its sponsored Level 1 American Depositary
Receipts (ADRs) commenced trading today on OTCQX International, a segment of the
OTCQX marketplace in the U.S., under the symbol ORXOY, with each ADR comprised
of 1 ordinary share.

OTCQX International is a segment of the OTCQX marketplace reserved for high
-quality non-U.S. companies that are listed on a qualified international
exchange, undergo management reviews and provide their home country disclosure
to U.S. investors. U.S. investors can find current financial disclosures and
Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

Henrik Juuel, EVP and Chief Financial Officer of Orexo commented: “Given our
increased presence in the U.S. following the launch of Zubsolv®, I am very
pleased that our ADRs are now trading on the OTCQX marketplace. OTCQX
International provides Orexo the opportunity to create a better informed and
more efficient marketplace for U.S.-based investors. Joining OTCQX will
complement our presence on the NASDAQ OMX Stockholm Exchange, while facilitating
and enhancing global trading in Orexo’s shares.”

Citibank N.A. has been appointed by Orexo as ADR depositary bank. Orexo’s
ordinary shares will continue to be listed and trade on the NASDAQ OMX Stockholm
Exchange under the symbol ORX.



For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com

About Sponsored Level 1 ADR program
ADRs are U.S. dollar-denominated negotiable instruments issued by a depositary
bank. They can represent a fraction of a share, a single share, or multiple
shares of the foreign stock. The price of an ADR often tracks the price of the
foreign stock in its home market, adjusted for the ratio of ADRs to the
company’s shares, but may vary according to other factors. Level 1 depositary
receipts are the first level of sponsored ADRs that can be issued and may only
be traded on the OTC market. When a company establishes a sponsored ADR program,
it appoints a depositary bank who also acts as its U.S. transfer agent. The
majority of sponsored ADR programs currently trading are Level 1 programs.

About Orexo AB
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology and commercial operations in the United States. The
company is commercializing its proprietary product, Zubsolv®, for maintenance
treatment of opioid dependence, in the United States. Zubsolv is a novel
formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in
sublingual technologies. Orexo has a portfolio of two approved and revenue
generating products currently marketed under license in the EU and US. Orexo AB,
with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange and
its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the
U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and
HealthCap.

For information about Orexo AB, please visit www.orexo.com.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 1:00 pm CET on November 13, 2013.